Loading clinical trials...

RECRUITING

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study

NCT06357403•Medical University of Vienna

View on ClinicalTrials.gov

Summary

The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are: * What is the association between antiXa and VTE? * What is the association between antiXa and symptomatic, respectively incidental, VTE? * How is pharmacological anticoagulation with enoxaparin related to measured antiXa? * What is the association between antiXa and bleeding complications. * What is the incidence of venous thromboembolism in patients treated at an intensive care unit? * How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age over 18 years at the time of intensive care unit admission
•Admission to a participating intensive care unit within the last 24 hours
•Expected discharge is later than 48 hours after enrolment

Exclusion Criteria

•Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE/kg when given twice daily or of at least 150 IE/kg when given once daily
•Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment
•Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period
•Estimated life expectancy below 48 hours or comfort terminal care order in place
•Previously diagnosed heparin-induced thrombocytopenia
•Pre-operative admission for elective surgery
•Previous enrolment in the study

Locations (2)

Department of Internal Medicine, Medical University of Graz

Graz, Styria, Austria

Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna

Vienna, Austria

Key Dates

Start Date

May 4, 2024

Primary Completion Date

May 1, 2027

Completion Date

August 1, 2027

Last Updated

September 29, 2025

Enrollment

1,300

ESTIMATED participants

Conditions

ThrombosisPulmonary EmbolismEnoxaparin

Interventions

Anti-factor Xa activity calibrated for enoxaparin

DIAGNOSTIC_TEST

Contacts

Christoph Dibiasi, MD

CONTACT

0043 1 40400 christoph.dibiasi@meduniwien.ac.at

Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

NCT06183944

Pulmonary Embolism

View study

RECRUITINGPHASE3

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117

Cancer-Associated Thrombosis (CAT)

View study

RECRUITINGNA

CLEANer Aspiration for Pulmonary Embolism

NCT06189313

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

Inclusion Criteria

Exclusion Criteria

Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

CLEANer Aspiration for Pulmonary Embolism

Positron Emission Tomography (PET) Imaging of Thrombosis

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke